Preliminary Communication

Clinical and molecular epidemiology of Acinetobacter baumannii bloodstream infections in an endemic setting

Dror Marchaim

*Author for correspondence:

E-mail Address: drormarchaim@gmail.com

Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin, Israel

Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Search for more papers by this author

Dana Levit

Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Search for more papers by this author

Roy Zigron

Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Search for more papers by this author

Michal Gordon

NIBN, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Search for more papers by this author

Tsillia Lazarovitch

Clinical Microbiology Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel

Search for more papers by this author

Joao A Carrico

Instituto de Microbiologia & Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal

Search for more papers by this author

Vered Chalifa-Caspi

NIBN, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Search for more papers by this author

Jacob Moran-Gilad

Public Health Services, Ministry of Health, Jerusalem, Israel

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

ESCMID Study Group for Genomic & Molecular Diagnostics (ESGMD), Basel, Switzerland

Search for more papers by this author

Published Online:24 Feb 2017https://doi.org/10.2217/fmb-2016-0158

View article

Abstract

Aim: The transmission dynamics of Acinetobacter baumannii in endemic settings, and the relation between microbial properties and patients’ clinical outcomes, are yet obscure and hampered by insufficient metadata. Methods & Results: Of 20 consecutive patients with A. baumannii bloodstream infection that were thoroughly analyzed at a single center, at least one transmission opportunity was evident for 85% of patients. This implies that patient-to-patient transmission is the major mode of A. baumannii acquisitions in health facilities. Moreover, all patients who died immediately (<24 h of admission) were infected with a single clone (ST457; relative risk = 1.6; p = 0.05). Conclusion: This preliminary analysis should prompt further investigation by mapping genomic virulence determinants among A. baumannii ST457 lineage compared with other strains.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg. Infect. Dis. 11(1), 22–29 (2005).Crossref, Medline, Google Scholar
2 Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1–12 (2009).Crossref, Medline, Google Scholar
3 Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin. Infect. Dis. 51(1), 79–84 (2010).Crossref, Medline, Google Scholar
4 Howard A, O'Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence 3(3), 243–250 (2012).Crossref, Medline, Google Scholar
5 Munoz-Price LS, Weinstein RA. Acinetobacter infection. N. Engl. J. Med. 358(12), 1271–1281 (2008). • A pivotal review of the epidemiology of Acinetobacter baumannii infections.Crossref, Medline, CAS, Google Scholar
6 Paul M, Weinberger M, Siegman-Igra Y et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997–2002. J. Hosp. Infect. 60(3), 256–260 (2005).Crossref, Medline, CAS, Google Scholar
7 Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21(3), 538–582 (2008).Crossref, Medline, CAS, Google Scholar
8 Gilad J, Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs 68(2), 165–189 (2008).Crossref, Medline, CAS, Google Scholar
9 Chopra T, Marchaim D, Awali RA et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob. Agents Chemother. 57(12), 6270–6275 (2013).Crossref, Medline, CAS, Google Scholar
10 Reddy T, Chopra T, Marchaim D et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob. Agents Chemother. 54(5), 2235–2238 (2010).Crossref, Medline, CAS, Google Scholar
11 Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur. J. Clin. Microbiol. Infect. Dis. 26(11), 793–800 (2007).Crossref, Medline, CAS, Google Scholar
12 Munoz-Price LS, Fajardo-Aquino Y, Arheart KL et al. Aerosolization of Acinetobacter baumannii in a trauma ICU*. Crit. Care Med. 41(8), 1915–1918 (2013).Crossref, Medline, Google Scholar
13 Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N. Engl. J. Med. 362(19), 1804–1813 (2010). • A pivotal review of the epidemiology of Gram-negative infections in hospital settings.Crossref, Medline, CAS, Google Scholar
14 Bonten MJ. Colonization pressure: a critical parameter in the epidemiology of antibiotic-resistant bacteria. Crit. Care 16(4), 142 (2012).Crossref, Medline, Google Scholar
15 Marchaim D, Navon-Venezia S, Schwartz D et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J. Clin. Microbiol. 45(5), 1551–1555 (2007). •• A comparative trial illustrating the challenges and difficulties associated with diagnosing asymptomatic carriers.Crossref, Medline, CAS, Google Scholar
16 Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51(10), 3471–3484 (2007).Crossref, Medline, CAS, Google Scholar
17 Marchaim D, Navon-Venezia S, Leavitt A, Chmelnitsky I, Schwaber MJ, Carmeli Y. Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital. Infect. Control Hosp. Epidemiol. 28(8), 945–950 (2007). •• A trial that focused on the transmission dynamics of A. baumannii in hospital endemic settings and was the first to quantify transmission opportunities between carriers.Crossref, Medline, Google Scholar
18 Smolyakov R, Borer A, Riesenberg K et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J. Hosp. Infect. 54(1), 32–38 (2003).Crossref, Medline, CAS, Google Scholar
19 Tal-Jasper R, Katz DE, Amrami N et al. Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrob. Agents Chemother. 60(5), 3127–3131 (2016). •• Examined the independent role of carbapenem resistance among A. baumannii strains associated with bloodstream infections.Crossref, Medline, CAS, Google Scholar
20 Qureshi ZA, Hittle LE, O'Hara JA et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin. Infect. Dis. 60(9), 1295–1303 (2015).Crossref, Medline, Google Scholar
21 Pogue JM, Cohen DA, Marchaim D. Editorial commentary: polymyxin-resistant Acinetobacter baumannii: urgent action needed. Clin. Infect. Dis. 60(9), 1304–1307 (2015).Medline, Google Scholar
22 Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin. Respir. Crit. Care Med. 36(1), 85–98 (2015).Crossref, Medline, Google Scholar
23 Ku K, Pogue JM, Moshos J et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am. J. Infect. Control. 40(10), 983–987 (2012).Crossref, Medline, CAS, Google Scholar
24 Wright MS, Iovleva A, Jacobs MR, Bonomo RA, Adams MD. Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Med. 8(1), 26 (2016).Crossref, Medline, Google Scholar
25 Chuang YC, Sheng WH, Lauderdale TL et al. Molecular epidemiology, antimicrobial susceptibility and carbapenemase resistance determinants among Acinetobacter baumannii clinical isolates in Taiwan. J. Microbiol. Immunol. Infect. 47(4), 324–332 (2014).Crossref, Medline, CAS, Google Scholar
26 Fitzpatrick MA, Ozer EA, Hauser AR. Utility of whole-genome sequencing in characterizing Acinetobacter epidemiology and analyzing hospital outbreaks. J. Clin. Microbiol. 54(3), 593–612 (2016). • A trial that studied the role of whole genome sequencing in analyzing A. baumannii infections during outbreaks and in endemic settings.Crossref, Medline, Google Scholar
27 Izwan I, Teh LK, Salleh MZ. The genome sequence of Acinetobacter baumannii isolated from a septicemic patient in a local hospital in Malaysia. Genom Data 6, 128–129 (2015).Crossref, Medline, CAS, Google Scholar
28 Hammerum AM, Hansen F, Skov MN et al. Investigation of a possible outbreak of carbapenem-resistant Acinetobacter baumannii in Odense, Denmark using PFGE, MLST and whole-genome-based SNPs. J. Antimicrob. Chemother. 70(7), 1965–1968 (2015). • A comparative trial that analyzed the best methodology to examined the molecular epidemiology of A. baumannii outbreaks.Medline, CAS, Google Scholar
29 Salipante SJ, Sengupta DJ, Cummings LA, Land TA, Hoogestraat DR, Cookson BT. Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology. J. Clin. Microbiol. 53(4), 1072–1079 (2015).Crossref, Medline, CAS, Google Scholar
30 Feng Y, Ruan Z, Shu J, Chen CL, Chiu CH. A glimpse into evolution and dissemination of multidrug-resistant Acinetobacter baumannii isolates in East Asia: a comparative genomics study. Sci. Rep. 6, 24342 (2016). • Analyzed the molecular epidemiology of A. baumannii on a broader level (continental).Crossref, Medline, CAS, Google Scholar
31 Tomaschek F, Higgins PG, Stefanik D, Wisplinghoff H, Seifert H. Head-to-head comparison of two multi-locus sequence typing (MLST) schemes for characterization of Acinetobacter baumannii outbreak and sporadic isolates. PLoS ONE 11(4), e0153014 (2016).Crossref, Medline, Google Scholar
32 Tamayo-Legorreta E, Turrubiartes-Martinez E, Garza-Ramos U et al. Outbreak caused by blaOXA-72-producing Acinetobacter baumannii ST417 detected in clinical and environmental isolates. Microb. Drug Resist. 22(2), 129–133 (2016).Crossref, Medline, CAS, Google Scholar
33 Kanamori H, Parobek CM, Weber DJ et al. Next-generation sequencing and comparative analysis of sequential outbreaks caused by multidrug-resistant Acinetobacter baumannii at a large academic burn center. Antimicrob. Agents Chemother. 60(3), 1249–1257 (2015).Crossref, Medline, Google Scholar
34 El-Shazly S, Dashti A, Vali L, Bolaris M, Ibrahim AS. Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii. Int. J. Infect. Dis. 41, 42–49 (2015).Crossref, Medline, CAS, Google Scholar
35 Piana A, Palmieri A, Deidda S et al. Molecular typing of XDR Acinetobacter baumannii strains in an Italian ICU. Epidemiol. Prev. 39(4 Suppl. 1), 129–133 (2015).Medline, Google Scholar
36 Villalon P, Valdezate S, Cabezas T et al. Endemic and epidemic Acinetobacter baumannii clones: a twelve-year study in a tertiary care hospital. BMC Microbiol. 15, 47 (2015).Crossref, Medline, Google Scholar
37 Marchaim D, Zaidenstein R, Lazarovitch T, Karpuch Y, Ziv T, Weinberger M. Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age. Eur. J. Clin. Microbiol. Infect. Dis. 27(11), 1045–1051 (2008).Crossref, Medline, CAS, Google Scholar
38 Dellinger RP, Levy MM, Carlet JM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36(1), 296–327 (2008).Crossref, Medline, Google Scholar
39 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control. 36(5), 309–332 (2008).Crossref, Medline, Google Scholar
40 Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268–281 (2012).Crossref, Medline, CAS, Google Scholar
41 Acinetobacter baumannii MLST (Pasteur) database.http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_abaumannii_pasteur_seqdef Google Scholar
42 Acinetobacter baumannii MLST (Oxford) database.http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_abaumannii_oxford_seqdef Google Scholar
43 PHYLOViZ.http://www.phyloviz.net/ Google Scholar
44 Francisco AP, Bugalho M, Ramirez M, Carrico JA. Global optimal eBURST analysis of multilocus typing data using a graphic matroid approach. BMC Bioinformatics 10, 152 (2009).Crossref, Medline, Google Scholar
45 Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373–383 (1987).Crossref, Medline, CAS, Google Scholar
46 Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. Jama 185, 914–919 (1963).Crossref, Medline, CAS, Google Scholar
47 Paterson DL, Ko WC, Von Gottberg A et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann. Intern. Med. 140(1), 26–32 (2004).Crossref, Medline, Google Scholar
48 Alp E, Esel D, Yildiz O, Voss A, Melchers W, Doganay M. Genotypic analysis of Acinetobacter bloodstream infection isolates in a Turkish university hospital. Scand. J. Infect. Dis. 38(5), 335–340 (2006).Crossref, Medline, CAS, Google Scholar
49 Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii. Clin. Microbiol. Infect. 6(12), 635–643 (2000).Crossref, Medline, CAS, Google Scholar
50 Giannouli M, Cuccurullo S, Crivaro V et al. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a tertiary care hospital in Naples, Italy, shows the emergence of a novel epidemic clone. J. Clin. Microbiol. 48(4), 1223–1230 (2010).Crossref, Medline, CAS, Google Scholar
51 Halachev MR, Chan JZ, Constantinidou CI et al. Genomic epidemiology of a protracted hospital outbreak caused by multidrug-resistant Acinetobacter baumannii in Birmingham, England. Genome Med. 6(11), 70 (2014).Crossref, Medline, Google Scholar
52 Endo S, Yano H, Hirakata Y et al. Molecular epidemiology of carbapenem-non-susceptible Acinetobacter baumannii in Japan. J. Antimicrob. Chemother. 67(7), 1623–1626 (2012).Crossref, Medline, CAS, Google Scholar
53 Fillaux J, Dubouix A, Conil JM, Laguerre J, Marty N. Retrospective analysis of multidrug-resistant Acinetobacter baumannii strains isolated during a 4-year period in a university hospital. Infect. Control. Hosp. Epidemiol. 27(7), 647–653 (2006).Crossref, Medline, Google Scholar
54 Royer S, Faria AL, Seki LM et al. Spread of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clones in patients with ventilator-associated pneumonia in an adult intensive care unit at a university hospital. Braz. J. Infect. Dis. 19(4), 350–357 (2015).Crossref, Medline, Google Scholar
55 Merkier AK, Catalano M, Ramirez MS et al. Polyclonal spread of bla(OXA-23) and bla(OXA-58) in Acinetobacter baumannii isolates from Argentina. J. Infect. Dev. Ctries 2(3), 235–240 (2008).Medline, Google Scholar
56 Marchaim D, Perez F, Lee J et al. “Swimming in resistance”: co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa. Am. J. Infect. Control. 40(9), 830–835 (2012).Crossref, Medline, Google Scholar
57 Perez F, Endimiani A, Ray AJ et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J. Antimicrob. Chemother. 65(8), 1807–1818 (2010).Crossref, Medline, CAS, Google Scholar
58 Harris AD, Pineles L, Belton B et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA 310(15), 1571–1580 (2013).Medline, CAS, Google Scholar
59 Choi WS, Kim SH, Jeon EG et al. Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program. J. Korean Med. Sci. 25(7), 999–1004 (2010).Crossref, Medline, Google Scholar
60 Coyle JR, Kaye KS, Taylor T et al. Effectiveness and cost of implementing an active surveillance screening policy for Acinetobacter baumannii: a Monte Carlo simulation model. Am. J. Infect. Control. 42(3), 283–287 (2014).Crossref, Medline, Google Scholar
61 Bogan C, Marchaim D. The role of antimicrobial stewardship in curbing carbapenem resistance. Future Microbiol. 8(8), 979–991 (2013).Link, CAS, Google Scholar

Vol. 12, No. 4

Metrics

Downloaded 155 times

History

Published online 24 February 2017

Published in print March 2017

Information

Keywords

Acknowledgements

This work was performed in partial fulfilment of the M.D. thesis requirements of the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel. This work was presented in part in the European Congress of Clinical Microbiology and Infectious Diseases, 25th annual meeting, at Copenhagen, Denmark (May 2015).

Financial & competing interests disclosure

This project has been partially funded by a Research Grant from the European Society for Microbiology and Infectious Diseases (granted to J Moran-Gilad). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download